1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program

 
• By Shirley Haley

Details from the COU-302 trial of Johnson & Johnson’s Zytiga, stopped early for efficacy in March, were released at the American Society of Clinical Oncology meeting, revealing to Medivation/Astellas insights on how to tweak their ongoing registrational trial for enzalutamide (MDV3100) in the pre-chemo prostate cancer space.

Medivation Inc./Astellas Pharma Inc. have been handed an opportunity to sharpen up the regulatory strategy for their prostate cancer drug enzalutamide (MDV3100) after data from the Phase III COUGAR-302 trial, testing Johnson & Johnson’s Zytiga (abiraterone) in pre-chemotherapy patients, were revealed at the American Society of Clinical Oncology meeting in Chicago.

The Zytiga trial was stopped in March after an interim analysis showed significant improvement in radiological progression-free survival for the J&J drug, allowing patients in the placebo arm to cross over to abiraterone

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 
• By Eliza Slawther

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.